Omega-3 Pharmaceutical Approved in Norway
LYSAKER, Norway--OMACOR, a high-potency formulation of omega-3s (EPA and DHA), was approved in Norway for the treatment of post-infarct patients. It shows similar therapeutic effects to other cardiovascular therapies such as anti-hypertensives, statins and anti-platelets. The formulation has also been approved in the United Kingdom, Germany, France, Austria and Greece. OMACOR was developed from research by Pronova Biocare (www.pronova.com).